Development and applications of two and three component particle image velocimetry techniques for simultaneous measurement in multi-phase flows and automative fuel sprays

The introduction of a new imaging approach for simultaneous multi-phase and multi-constituent velocity measurements is the main focus of this research. The proposed approach is based on the use of a single off-the-shelf colour camera which will enable simultaneous imaging of phases/constituents which are colourtagged using fluorescent droplets and multi-wavelength illumination. Highly efficient florescent tracers used to seed the constituents are presented and their visibility in full field imaging experiments is evaluated. A commonly found problem in experimental systems using laser illumination, known as flare, is discussed and the application of the developed fluorescent tracers for its reduction is presented. A strong focus of the imaging approach proposed is its flexibility and simplicity allowing its extension to stereoscopic imaging to obtain simultaneous multi-phase/constituent 3-component measurements with the addition of a second imaging camera. Proof of principle experiments with spatially separated and well mixed flows are presented for which successful phase discrimination is obtained and the uncertainty of the measurements is estimated. The imaging system developed is applied for simultaneous air and fuel velocimetry measurements in a Gasoline Direct Injection spray for which a more detailed understating of the interaction mechanisms is required to generate improved designs. The modified imaging system and experimental setup are presented and previously unavailable simultaneous air/fuel 2 and 3-component velocity fields are presented and analysed.EThOS - Electronic Theses Online ServiceGBUnited Kingdo

Contributo alla conoscenza dei Briozoi marini di Capo di Murro di Porco, penisola della Maddalena (Siracusa)

EnA list of Bryozoa (2 Ctenostomata,20 Cheilostomata,1 Cyclostomata) collected at Cape Murro di Porco (Syracuse, Sicily) is produced. The A. gives some informations on the characteristics of the substratum and data about the status of the colonies. 6 species have never been mentioned to Sicily by other Authors

The influence of high dose intravenous immunoglobulins on immunological and metabolic pattern in newly diagnosed type I diabetic patients

In autoimmune disease the functional deficiency of T suppressor cells, also described in Type I diabetes, may be restored through immunoglobulin (Ig) infusion, which increases antigen phagocytosis, NK activity, cell clones and antibody anti-idiotype responses. Sixteen Type I diabetic patients were studied: eight were treated soon after the initial correction of disease-onset glycemic deterioration with intensive intravenous (i.v.) 7S Ig treatment (0.4 g/kg/BW) for 1 week and once per week for 6 months, whilst the remaining patients constituted the control group. All patients were evaluated during the study for metabolic and immunological parameters. A reduction in insulin requirement compared to conventionally treated patients was observed at the third (0.17±0.06 vs 0.44±0.08 IU/kg/BW; P<0.02) and at the sixth month of therapy (0.19±0.07 vs 0.54±0.07 IU/kg/BW; P<0.005). Two patients ceased to require insulin therapy within the first month, showing a prolonged restoration of B-cell function. Serum C-peptide values were also significantly higher in the Ig-treated group compared to the control group after 3 and 6 months. As regards immunological parameters, patients showed a decrease in insulin antibody levels and a reduction in TAC + cells. Intravenous Ig therapy seems able to affect positively the first phases of metabolic and immunological deterioration of Type I diabetes

Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS)

BackgroundGuselkumab is a humanized monoclonal antibody that binds selectively to the p19 subunit of interleukin-23, which has shown efficacy in patients with previous incomplete response to ustekinumab in the NAVIGATE clinical trial. ObjectivesWe conducted a 104-week multicenter retrospective study to assess the effectiveness and safety of guselkumab in patients affected by plaque psoriasis with an inadequate response to ustekinumab in a real-life setting. MethodsOur retrospective study included 233 adults affected by moderate-to-severe plaque psoriasis, enrolled in 14 different Italian centres, and treated with guselkumab after failing therapy with ustekinumab. Patient characteristics and PASI (Psoriasis Area and Severity Index) score at each visit (baseline, weeks 16, 52 and 104) were recorded. The percentages of patients achieving 75%, 90% and 100% (PASI 75, PASI 90 and PASI 100) improvement in PASI, compared with baseline, were registered. ResultsAt week 52, PASI 75 was reached by 89.88% of patients, PASI 90 by 71.43%, PASI 100 by 58.83% and absolute PASI &lt;= 2 by 90.48%. At week 104, similar effectiveness results were observed. Compared to the NAVIGATE trial, we observed higher rates of PASI 75/90/100. Patients with the involvement of difficult-to-treat areas were significantly less likely to achieve PASI90 and PASI100 at week 16. Obese patients had significantly lower rates of PASI75 and PASI &lt;= 2 at week 52. At week 104, comparable responses were observed among all patients' subgroups, regardless of BMI status, involvement of difficult-to-treat areas, presence of cardiometabolic comorbidities and concomitant psoriatic arthritis. No significant safety findings were reported throughout the study. ConclusionOur data suggest that the efficacy of guselkumab in patients with inadequate response to ustekinumab for plaque psoriasis in 'real-life' clinical practice is comparable with NAVIGATE study with higher percentages of patients achieving PASI90 and PASI100 at weeks 16, 52 and 104

Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement

the place in therapy of brodalumab in patients with psoriasi